TPG Biotech

TPG Biotech is the life sciences venture capital platform of TPG, a global alternative asset management firm. Established in 2002, TPG Biotech focuses on investing in pharmaceutical discovery and development, medical technology, diagnostics, healthcare and pharmaceutical services, life sciences, and industrial applications of biotechnology. The firm leverages TPG's extensive resources and expertise to support companies developing disruptive science, technologies, and business models aimed at improving patient outcomes in areas with significant unmet medical needs.

TPG Biotech's investment strategy is thematic, concentrating on sectors such as oncology, autoimmune and inflammatory diseases, cardiometabolic diseases, ophthalmology, rare diseases, as well as commercial-stage medical devices and tech-enabled services. The team brings deep scientific, clinical, and operational expertise to its investments, partnering with companies from early-stage development through clinical trials to commercialization. This approach is built upon TPG's market-leading healthcare franchise, which has invested over $30 billion across the global healthcare ecosystem since 2003.

The firm has a strong track record of supporting innovative companies in the biotechnology sector. Notable investments include Allogene Therapeutics, a clinical-stage biotechnology company focused on pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and Nextech, a leading provider of clinical and administrative healthcare technology solutions for specialty physician practices. TPG Biotech's commitment to advancing healthcare innovation is further demonstrated through its participation in significant funding rounds for companies like Sionna Therapeutics and Santa Ana Bio, contributing to the advancement of breakthrough technologies in the life sciences sector.